Effects of policosanol on the susceptibility of low-density lipoprotein isolated from hypercholesterolemic patients at high coronary risk to in vitro copper-mediated lipid peroxidation: A randomized, double-blind pilot study

Current Therapeutic Research - Clinical and Experimental

Volumn 61, Issue 9, 2000, Pages 609-620

  Menéndez, Roberto ^a   Más, Rosa ^a   Amor, Ana María ^a   Fernández, Julio Cesar ^a   González, Rosa María ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Copper mediated oxidation; Hypercholesterolemic patients; Low density lipoprotein peroxidation; Policosanol

Indexed keywords

COPPER ION; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033823403     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(00)88013-3     Document Type: Article

References (51)

1. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity
2. Modified forms of low density lipoprotein and atherosclerosis
3. Lipid peroxidation and its role in atherosclerosis
4. Free radical modification of low-density lipoprotein: Mechanism and biological consequences
5. Role of oxidatively modified LDL in atherosclerosis
6. Studies on hypercholesterolemia in nonhuman primates. II. Fatty streak conversion to fibrous plaque
7. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbits and man
8. Low density lipoprotein undergoes oxidative modification in vivo
9. Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherosclerosis
10. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocyte cell line U937
11. Oxidized LDL-induced leukocyte/endothelium interaction in vivo involves the receptor for platelet-activating factor
12. Malondialdehyde affects the physico-chemical and biological characteristic of oxidized low density lipoprotein
13. Modified forms of low density lipoprotein affect platelet aggregation in vitro
14. Enhanced procoagulatory activity (PCA) of human monocytes/macrophages after in vitro stimulation with chemically modified LDL
15. Platelet secretory substances enhance in vitro plasma coagulation
16. Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients
17. Oxidative status of lipoproteins in coronary disease patients
18. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man
19. Predisposition to LDL oxidation in patients with and without angiographically established coronary artery disease
20. Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages A possible role for angiotensin II
21. Lipid peroxide levels of serum lipoprotein fractions of diabetic patients
22. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: In vitro and in vivo studies
23. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl CoA reductase
24. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL
25. Effect of probucol treatment on the susceptibility of low density lipoprotein isolated from hypercholesterolemic patients to become oxidatively modified in vitro
26. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans
27. Effect of low-dose probucol on LDL oxidation and the plasma lipoprotein profile in male volunteers
28. Effects of policosanol on serum lipids and lipoprotein in healthy volunteers
29. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment
30. Effects of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia
31. One-year study of the efficacy and safety of policosanol (5 mg twice-a-day) in the treatment of type II hypercholesterolemia
32. A two-year study of the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia
33. Effects of policosanol on hypercholesterolemic patients with disturbances in serum biochemical indicators of hepatic function
34. A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia
35. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia
36. A long-term open study of the efficacy and tolerability of policosanol in patients with high global coronary risk
37. Effects of policosanol in patients with type II hyper-cholesterolemia and additional coronary risk factors
38. Treatment of hypercholesterolemia in NIDDM with policosanol
39. Effects of policosanol in patients with non-insulin-dependent diabetes mellitus (NIDDM) and hypercholesterolemia
40. Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts
41. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet
42. Effects of policosanol on in vitro and in vivo rat liver microsomal lipid peroxidation
43. Oral administration of policosanol inhibits in vitro copper ion-induced rat lipoprotein peroxidation
44. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro
45. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals
46. Separation of serum high-density lipoprotein for cholesterol determination: Ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride
47. Estimation of the concentration of low-density lipoprotein in cholesterol in plasma, without use of the preparative ultracentrifuge
48. Improved measurements of low-density lipoprotein susceptibility to copper-induced oxidation: Application of a short procedure for isolating low-density lipoprotein
49. Continuous monitoring of in vitro oxidation of human low density lipoprotein
50. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples
51. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)